Purpose: The purpose of this guideline amendment, herein referred to as the amendment, is
to incorporate relevant newly published literature to better provide a clinical framework for …

The pharmacological treatment of urinary incontinence Page 1 BJU International (1999), 84,
923–947 REVIEW The pharmacological treatment of urinary incontinence K.-E …

Purpose: Overactive bladder affects 12% to 17% of the general population and almost a
third experience urinary incontinence, which may severely impact health related quality of …

Introduction and hypothesis Many adult women have resident urinary bacteria (urinary
microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the …

Purpose: Treatment options for patients with overactive bladder refractory to anticholinergics
are limited. We assessed the dose response across a range of doses of onabotulinumtoxinA …

CONTEXT: The European Association of Urology (EAU) guidelines on urinary incontinence
published in March 2012 have been rewritten based on an independent systematic review …

Background Anticholinergic medications and onabotulinumtoxinA are used to treat urgency
urinary incontinence, but data directly comparing the two types of therapy are needed …

Background Overactive bladder syndrome (OAB) is a common condition with a significant
negative impact on quality of life characterised by urgency with or without urge incontinence …

CONTEXT: The use of botulinum toxin A (BoNTA) in the treatment of lower urinary tract
dysfunction has expanded in recent years and the off-licence usage list includes neurogenic …

BACKGROUND: Emerging data suggest botulinum toxin is an effective treatment for
detrusor overactivity (DO), but large studies confirming efficacy and safety are lacking …